William Frank Iv Hulse Sells 54,596 Shares of MiMedx Group, Inc. (NASDAQ:MDXG) Stock

MiMedx Group, Inc. (NASDAQ:MDXG) CAO William Frank Iv Hulse sold 54,596 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the sale, the chief accounting officer now owns 440,178 shares of the company’s stock, valued at approximately $3,473,004.42. This trade represents a 11.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

William Frank Iv Hulse also recently made the following trade(s):

• On Monday, March 10th, William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock. The stock was sold at an average price of $7.80, for a total value of $635,278.80.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG opened at $7.92 on Friday. The business has a 50 day moving average price of $8.45 and a 200 day moving average price of $7.82. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The company has a market cap of $1.17 billion, a price-to-earnings ratio of 14.40 and a beta of 1.97. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. Research analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Institutional Trading of MiMedx Group

Several hedge funds have recently added to or reduced their stakes in MDXG. Jane Street Group LLC lifted its position in shares of MiMedx Group by 133.6% in the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock worth $1,806,000 after acquiring an additional 174,797 shares during the period. JPMorgan Chase & Co. lifted its position in shares of MiMedx Group by 265.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock worth $1,757,000 after acquiring an additional 215,995 shares during the period. Barclays PLC lifted its position in shares of MiMedx Group by 163.9% in the 3rd quarter. Barclays PLC now owns 262,449 shares of the company’s stock worth $1,550,000 after acquiring an additional 163,005 shares during the period. SG Americas Securities LLC lifted its position in shares of MiMedx Group by 79.9% in the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company’s stock worth $802,000 after acquiring an additional 37,031 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of MiMedx Group by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock worth $328,000 after acquiring an additional 3,292 shares during the period. Institutional investors own 79.15% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price target on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.